中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2015年
15期
2828-2831
,共4页
Nano无载体药物支架%Partner药物支架%炎症因子%主要不良心脏事件
Nano無載體藥物支架%Partner藥物支架%炎癥因子%主要不良心髒事件
Nano무재체약물지가%Partner약물지가%염증인자%주요불양심장사건
Polymer-free sirolimus-eluting Nano stent%Sirolimus-eluting Partner stent%Plasma proinflammatory cytokines%Major adverse cardiac events
目的：观察国产 Nano 无载体药物支架对血清炎症因子的影响，并探讨其对减少主要不良心脏事件的作用。方法选择2012年1月至2013年10月我院拟行经皮冠状动脉介入治疗（PCI）术的冠心病患者59例随机分为Partner组和Nano组，分别用ELISA法检测术前、术后24 h、1个月、3个月、6个月及12个月血清炎症因子高敏C反应蛋白（hsCRP）、白细胞介素-6（IL-6）、基质金属蛋白酶-9（MMP-9）；术后1、3、6、10、12个月门诊或电话随访，观察有无主要不良心脏事件。结果25例患者成功置入Partner药物支架，34例置入Nano无载体药物支架。Partner组和Nano组术前基本情况无明显差异，术后24 h hsCRP、IL-6、MMP-9均达到最高值；术前、术后24 h、术后1、3个月两组间hsCRP、IL-6、MMP-9无明显差异（P＞0.05）；术后6个月Partner组IL-6、MMP-9明显高于Nano组（P＜0.05），但两组间hsCRP无明显差异（P＞0.05）；术后12个月Partner组炎症因子hsCRP、IL-6、MMP-9均明显高于Nano组（P均＜0.05）。随访期间Partner组发生主要不良心脏事件明显高于Nano组（P＜0.05）。结论 Nano组较Partner组炎症反应更低，进一步减少支架置入术后主要不良心脏事件，考虑与去除载体有关。
目的：觀察國產 Nano 無載體藥物支架對血清炎癥因子的影響，併探討其對減少主要不良心髒事件的作用。方法選擇2012年1月至2013年10月我院擬行經皮冠狀動脈介入治療（PCI）術的冠心病患者59例隨機分為Partner組和Nano組，分彆用ELISA法檢測術前、術後24 h、1箇月、3箇月、6箇月及12箇月血清炎癥因子高敏C反應蛋白（hsCRP）、白細胞介素-6（IL-6）、基質金屬蛋白酶-9（MMP-9）；術後1、3、6、10、12箇月門診或電話隨訪，觀察有無主要不良心髒事件。結果25例患者成功置入Partner藥物支架，34例置入Nano無載體藥物支架。Partner組和Nano組術前基本情況無明顯差異，術後24 h hsCRP、IL-6、MMP-9均達到最高值；術前、術後24 h、術後1、3箇月兩組間hsCRP、IL-6、MMP-9無明顯差異（P＞0.05）；術後6箇月Partner組IL-6、MMP-9明顯高于Nano組（P＜0.05），但兩組間hsCRP無明顯差異（P＞0.05）；術後12箇月Partner組炎癥因子hsCRP、IL-6、MMP-9均明顯高于Nano組（P均＜0.05）。隨訪期間Partner組髮生主要不良心髒事件明顯高于Nano組（P＜0.05）。結論 Nano組較Partner組炎癥反應更低，進一步減少支架置入術後主要不良心髒事件，攷慮與去除載體有關。
목적：관찰국산 Nano 무재체약물지가대혈청염증인자적영향，병탐토기대감소주요불양심장사건적작용。방법선택2012년1월지2013년10월아원의행경피관상동맥개입치료（PCI）술적관심병환자59례수궤분위Partner조화Nano조，분별용ELISA법검측술전、술후24 h、1개월、3개월、6개월급12개월혈청염증인자고민C반응단백（hsCRP）、백세포개소-6（IL-6）、기질금속단백매-9（MMP-9）；술후1、3、6、10、12개월문진혹전화수방，관찰유무주요불양심장사건。결과25례환자성공치입Partner약물지가，34례치입Nano무재체약물지가。Partner조화Nano조술전기본정황무명현차이，술후24 h hsCRP、IL-6、MMP-9균체도최고치；술전、술후24 h、술후1、3개월량조간hsCRP、IL-6、MMP-9무명현차이（P＞0.05）；술후6개월Partner조IL-6、MMP-9명현고우Nano조（P＜0.05），단량조간hsCRP무명현차이（P＞0.05）；술후12개월Partner조염증인자hsCRP、IL-6、MMP-9균명현고우Nano조（P균＜0.05）。수방기간Partner조발생주요불양심장사건명현고우Nano조（P＜0.05）。결론 Nano조교Partner조염증반응경저，진일보감소지가치입술후주요불양심장사건，고필여거제재체유관。
ObjectiveTo study the effect of polymer-free sirolimus-eluting Nano stent implantation on plasma proinflammatory cytokines.MethodsFrom January 2012 to October 2013, 59 patients with coronary heart disease treated with primary percutaneous coronary intervention (PCI) were enroled and randomly divided into Partner and Nano group. Plasma proinflammatory cytokines high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6) and matrix metaloproteinases 9 (MMP-9) were detected by ELISA in the preoperative and postoperative 24 hours, 1 month, 3 months, 6 months and 12 months. All patients were folowed up in postoperative 1, 3, 6, 10, 12 months. The major adverse cardiac events (MACE) were analyzed.Results25 patients were implanted Partner stents and 34 patients were implanted Nano stents. Immediate success rate of postoperation was 100%. There was no difference on the preoperative basic situation between Partner and Nano group. The concentration of hsCRP, IL-6, MMP-9 achieved the highest in postoperative 24 hours. There was no difference on the concentration of hsCRP, IL-6, MMP-9 in preoperative and postoperative 24 hours, 1 month, 3 months between Partner and Nano group. Plasma IL-6, MMP-9 of Partner group were significantly higher than that of Nano group (P<0.05), but there was no difference in plasma hsCRP (P>0.05) in postoperative 6 months between two groups. Plasma hsCRP, IL-6 and MMP-9 of Partner group were significantly higher than that of Nano group in postoperative 12 months (alP<0.05). There were more MACE in Partner group than Nano group during the 12 months folow-up (P<0.05).ConclusionsNano group had lower inflammatory response and less MACE after stent implantation, that was related to get rid of the carrier.
